Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
Dr. Chand held several leadership positions within AstraZeneca and the broader biopharmaceutical industry
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
Subscribe To Our Newsletter & Stay Updated
